Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, +1432

The Lancet

Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseHealth PolicyCardiovascular Outcomes +7

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, +1434

The Lancet

Metabolic SyndromeDiabetes ManagementUrologyChronic Kidney DiseaseDiabetes +8

Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes

Michaela Waibel, John M. Wentworth, Michelle So, +18

New England Journal of Medicine

Proinsulin C-peptide is an autoantigen in people with type 1 diabetes

Michelle So, Colleen M. Elso, Eleonora Tresoldi, +11

Proceedings of the National Academy of Sciences

Combination product of dermal matrix, human mesenchymal stem cells, and timolol promotes diabetic wound healing in mice

Hsin‐ya Yang, Fernando A. Fierro, Michelle So, +13

Stem Cells Translational Medicine

Homeobox Genes are Differentially Expressed in Macrovascular Human Umbilical Vein Endothelial Cells and Microvascular Placental Endothelial Cells

Padma Murthi, Michelle So, N.M. Gude, +3

Placenta

AngiogenesisDevelopmental BiologyNatural SciencesVascular BiologyCord Blood +6

Characterising the age-dependent effects of risk factors on type 1 diabetes progression

Michelle So, Colin O’Rourke, Alyssa Ylescupidez, +7

Diabetologia

Topical Fluoxetine as a Novel Therapeutic That Improves Wound Healing in Diabetic Mice

Chuong Nguyen, Danielle Tartar, Michelle D. Bagood, +14

Diabetes

InflammationSerotonin PathwayTranslational MedicineTopical FluoxetineAnti-inflammatory +12

Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody–Positive Individuals

Michelle So, Colin O’Rourke, Henry T. Bahnson, +2

Diabetes Care

Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)—study protocol for a phase 2, randomized, placebo controlled trial

M. Waibel, Helen E. Thomas, John M. Wentworth, +7

Trials